Biogen is cutting ties with Aduhelm, the Alzheimer’s disease drug that won a landmark but controversial regulatory approval and then became a commercial flop. Development and commercialization of ...
For Biogen’s ill-fated Alzheimer’s disease drug Aduhelm, a narrow Medicare reimbursement policy is taking a toll beyond sales and on the company’s clinical development plan. Biogen has pulled the plug ...
More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Biogen is discontinuing the Alzheimer's disease therapy after walking a rocky path. Wednesday, Biogen said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback